Emerging synthetic drugs for the treatment of liver cirrhosis

References

• Paik JM, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72(5):1605–1616.
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133.
   PubMed Web of Science ®Google Scholar
• Sepanlou SG, Safiri S, Bisignano C; GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245–266.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Henry L. Overall health-related quality of life in patients with end-stage liver disease. Clin Liver Dis. 2015;6(1):9–14.
   Google Scholar
• D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231.
   PubMed Web of Science ®Google Scholar
• Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272–1284.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Friedman SL, McCullough AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American association for the study of liver diseases-U.S. Food and drug administration joint workshop. Hepatology. 2015;61(4):1392–1405.
   PubMed Web of Science ®Google Scholar
• Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2):100067.
   PubMedGoogle Scholar
• Ripoll C, Groszmann R, Garcia-Tsao G. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–488.
   PubMed Web of Science ®Google Scholar
• Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56(5):1171–1180.
   PubMed Web of Science ®Google Scholar
• Mallet V, Gilgenkrantz H, Serpaggi J, et al., Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149(6):399–403.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Everson GT, Calleja JL, et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24(10):823–831.
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the sportdiet study. Hepatology. 2017;65(4):1293–1305.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Invernizzi F, Viganò M, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol. 2015;63(5):1118–1125.
   PubMed Web of Science ®Google Scholar
• Lackner C, Spindelboeck W, Haybaeck J, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66(3):610–618.
   PubMed Web of Science ®Google Scholar
• Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52(2):176–182.
   PubMed Web of Science ®Google Scholar
• Lens S, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol. 2020;73(6):1415–1424.
   PubMed Web of Science ®Google Scholar
• Alvarez MA, Cirera I, Solà R, et al. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol. 2011;45(10):906–911.
   PubMed Web of Science ®Google Scholar
• Lassailly G, Caiazzo R, Ntandja-Wandji L-C, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159(4):1290–1301.e5.
   PubMed Web of Science ®Google Scholar
• Chang -T-T, Liaw Y-F, Wu -S-S, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–893.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460.
   PubMed Web of Science ®Google Scholar
• Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut. 2020;69(5):953–962.
   PubMed Web of Science ®Google Scholar
• Schierwagen R, Maybüchen L, Hittatiya K, et al. Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol Gastrointest Liver Physiol. 2016;311(4):G724–G733.
   PubMed Web of Science ®Google Scholar
• Trebicka J, Hennenberg M, Laleman W, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46(1):242–253.
   PubMed Web of Science ®Google Scholar
• Milliman Insight. 2020 U.S. organ and tissue transplants: cost estimates, discussion, and emerging issues; 2020 Feb 18 [cited 2020 Dec 14]; Available from: https://www.milliman.com/en/insight/2020-us-organ-and-tissue-transplants
   Google Scholar
• NHS Blood and Transplant. ANNUAL REPORT ON LIVER TRANSPLANTATION; 2020 Aug [cited 2020 Dec 14; Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/16782/nhsbt-liver-transplantation-annual-report-2018-19.pdf
   Google Scholar
• Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2020;S1542-3565(20):30775–30778.
   Google Scholar
• Hicks DF, Goossens N, Blas-García A, et al. Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Sci Rep. 2017;7(1):42563.
   PubMedGoogle Scholar
• Deng J, Wei W, Chen Z. Engineered liver-on-a-Chip platform to mimic liver functions and its biomedical applications: a review. Micromachines. 2019;10(10):676.
   Web of Science ®Google Scholar
• Paish HL, Reed LH, Brown H, et al. Technology for modeling fibrosis in human and rodent precision-Cut liver slices. Hepatology. 2019;70(4):1377–1391.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Rossi SJ, Paredes AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71(4):1198–1212.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Sanyal A, Harrison SA, et al., Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology. 2020;72(3):892–905.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Dennis A, Fiore MM, et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS One. 2018;13(9):e0203054.
   PubMed Web of Science ®Google Scholar
• Jayakumar S, Middleton MS, Lawitz EJ, et al., Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib. J Hepatol. 2019;70(1):133–141.
   PubMed Web of Science ®Google Scholar
• Liu F, Goh G-B-B, Tiniakos D, et al., qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71(6):1953–1966.
   PubMed Web of Science ®Google Scholar
• Burton JR Jr, Helmke S, Lauriski S, et al. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology. Transl Res. 2021;S1931-5244(20):30321–30322.
   Google Scholar
• Qi X, Berzigotti A, Cardenas A, et al. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018;3(10):708–719.
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Iredale JP, Fallowfield JA. Resolution of liver fibrosis: basic mechanisms and clinical relevance. Semin Liver Dis. 2015;35(2):119–131.
   PubMed Web of Science ®Google Scholar
• Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181–194.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Kamiya A, Sumiyoshi H, et al. A deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice. Hepatology. 2020;71(4):1437–1452.
   PubMed Web of Science ®Google Scholar
• Fallowfield JA, Hayden AL, Snowdon VK, et al. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology. 2014;59(4):1492–1504.
   PubMed Web of Science ®Google Scholar
• Fuchs BC, Hoshida Y, Fujii T, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014;59(4):1577–1590.
   PubMed Web of Science ®Google Scholar
• Sato Y, Murase K, Kato J, et al., Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26(4):431–442.
   PubMed Web of Science ®Google Scholar
• Oakley F, Meso M, Iredale JP, et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology. 2005;128(1):108–120.
   PubMed Web of Science ®Google Scholar
• DeLeve LD, Maretti-Mira AC. Liver sinusoidal endothelial cell: an update. Semin Liver Dis. 2017;37(4):377–387.
   PubMed Web of Science ®Google Scholar
• Gracia-Sancho J, Caparrós E, Fernández-Iglesias A, et al. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol. 2021. 10.1038/s41575-020-00411-3.
   PubMed Web of Science ®Google Scholar
• Duffield JS, Forbes SJ, Constandinou CM, et al., Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005;115(1):56–65.
   PubMed Web of Science ®Google Scholar
• Karlmark KR, Weiskirchen R, Zimmermann HW, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology. 2009;50(1):261–274.
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Pellicoro A, Vernon MA, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A. 2012;109(46):E3186–95.
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Dobie R, Wilson-Kanamori JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 2019;575(7783):512–518.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67(5):1754–1767.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther. 2016;44(11–12):1183–1198.
   PubMed Web of Science ®Google Scholar
• Bartneck M, Scheyda KM, Warzecha KT, et al. Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials. 2015;37:367–382.
   PubMed Web of Science ®Google Scholar
• Abe H, Kamimura K, Kobayashi Y, et al. Effective prevention of liver fibrosis by liver-targeted hydrodynamic gene delivery of matrix metalloproteinase-13 in a rat liver fibrosis model. Mol Ther Nucleic Acids. 2016;5(1):e276.
   PubMedGoogle Scholar
• Kallis YN, Robson AJ, Fallowfield JA, et al. Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response. Gut. 2011;60(4):525–533.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Bell A, Brooks JM, et al. Resetting the transcription factor network reverses terminal chronic hepatic failure. J Clin Invest. 2015;125(4):1533–1544.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922.
   PubMed Web of Science ®Google Scholar
• Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-Alcohol-Producing klebsiella pneumoniae. Cell Metab. 2019;30(4):675–688.e7.
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009–1017.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Abdelmalek MF, Caldwell S, et al., Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155(4):1140–1153.
   PubMed Web of Science ®Google Scholar
• Muir AJ, Levy C, Janssen HLA, et al. Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease. Hepatology. 2019;69(2):684–698.
   PubMed Web of Science ®Google Scholar
• Yamamoto E, Dong Y-F, Kataoka K, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension. 2008;52(3):573–580.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Wong VW-S, Okanoue T, et al., Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26–39. .
   PubMed Web of Science ®Google Scholar
• Gracia-Sancho J, Manicardi N, Ortega-Ribera M, et al. Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-Mediated paracrine mechanism. Hepatol Commun. 2019;3(7):987–1000.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020;72(5):816–827.
   PubMedGoogle Scholar
• Garcia-Tsao G, Bosch J, Kayali Z, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020;72(5):885–895.
   PubMed Web of Science ®Google Scholar
• Frenette C, Kayali Z, Mena E, et al. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J Hepatol. 2020;S0168-8278(20):33673–33674.
   Google Scholar
• Traber PG, Chou H, Zomer E, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One. 2013;8(10):e75361.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al., Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158(5):1334–1345.e5.
   PubMed Web of Science ®Google Scholar
• Shah RA, Alkhouri N, Kowdley KV. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. Expert Opin Emerg Drugs. 2020;25(3):251–260.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R, et al., Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–2196. .
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Van Natta ML, Connell MA, et al. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatol. 2020;72(1):25–33.
   PubMed Web of Science ®Google Scholar
• Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11(6):e0158156.
   PubMed Web of Science ®Google Scholar
• Mitchell C, Couton D, Couty J-P, et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol. 2009;174(5):1766–1775.
   PubMed Web of Science ®Google Scholar
• Lin Z, Tian H, Lam KSL, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17(5):779–789.
   PubMed Web of Science ®Google Scholar
• Charles ED, Neuschwander-Tetri BA, Frias JP, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity. 2019;27(1):41–49.
   PubMed Web of Science ®Google Scholar
• Sanyal A, Charles ED, Neuschwander-Tetri BA, et al., Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019;392(10165):2705–2717.
   PubMed Web of Science ®Google Scholar
• Kaufman A, Abuqayyas L, Denney WS, et al., AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep Med. 2020;1(4):100057.
   PubMedGoogle Scholar
• Zhou M, Learned RM, Rossi SJ, et al. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1(10):1024–1042.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Chazouillères O, Drenth JP, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol. 2019;70(3):483–493.
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Wigg AJ, Leggett BA, et al. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun. 2018;2(9):1037–1050.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Neff G, Guy CD, et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology. 2020;S0016-5085(20):35018.
   Google Scholar
• Lawitz E, Shevell D, Revankaret R, et al. BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomised, double-blind, placebo-controlled trial [abstract]. J Hepatol. 2020;73:S123–S400.
   Google Scholar
• Kluwe J, Pradere J-P, Gwak G-Y, et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology. 2010;138(1):347–359.
   PubMed Web of Science ®Google Scholar
• Greenberg S, Horan G, Bennett B, et al. Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial [abstract]. Eur Respir J. 2017;50:OA474.
   Google Scholar
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155.
   PubMed Web of Science ®Google Scholar
• Rakipovski G, Rolin B, Nøhr J, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE -/- and LDLr -/- Mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018;3(6):844–857.
   PubMedGoogle Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-Controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2020;384(12):1113–1124.
   PubMed Web of Science ®Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251.
   PubMed Web of Science ®Google Scholar
• Bates J, Vijayakumar A, Ghoshal S, et al. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J Hepatol. 2020;73(4):896–905.
   PubMedGoogle Scholar
• Loomba R, Kayali Z, Noureddin M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155(5):1463–1473.
   PubMed Web of Science ®Google Scholar
• Loomba R, Noureddin M, Kowdley KV, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH. Hepatology. 2020;73:S116–S117.
   Web of Science ®Google Scholar
• Schwabl P, Hambruch E, Budas GR, et al. The non-Steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model. Biomedicines. 2021;9(1):60.
   PubMed Web of Science ®Google Scholar
• Patel K, Harrison SA, Elkhashab M, et al., Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology. 2020;72(1):58–71.
   PubMed Web of Science ®Google Scholar
• Kim Y, Natarajan SK, Chung S. Gamma-Tocotrienol ATTENUATES THE HEPATIC INflAMMATION AND FIBROSIS BY SUPPRESSING ENDOPLASMIC RETICULUM STRESS IN MICE. Mol Nutr Food Res. 2018;62(21):1800519.
   Web of Science ®Google Scholar
• Patel V, Rink C, Gordillo GM, et al. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012;142(3):513–519.
   PubMed Web of Science ®Google Scholar
• Osawa Y, Oboki K, Imamura J, et al. Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response element-binding protein (CREB)-binding protein (CBP)/beta-Catenin reduces liver fibrosis in mice. EBioMedicine. 2015;2(11):1751–1758.
   PubMed Web of Science ®Google Scholar
• Nishikawa K, Osawa Y, Kimura K. Wnt/β-Catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs. Int J Mol Sci. 2018;19(10):3103.
   Web of Science ®Google Scholar
• Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science. 2010;329(5988):229–232.
   PubMed Web of Science ®Google Scholar
• Liang D, Chen H, Zhao L, et al. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease. Biochim Biophys Acta Mol Basis Dis. 2018;1864(1):133–142.
   PubMed Web of Science ®Google Scholar
• Dufour J-F, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69(10):1877–1884.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Herring RW Jr, Kabler H, et al. Safety and efficacy of combination therapies including semaglutide, cilofexor, and firsocostat in patients with NASH [abstract]. Hepatology. 2020;72(S1):L02A.
   Google Scholar
• Glass O, Filozof C, Noureddin M, et al. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: recommendations from the liver forum. J Hepatol. 2020;73(3):680–693.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Nonalcoholic steatohepatitis with compensated cirrhosis: developing drugs for treatment guidance for industry; 2019 June [cited 2020 Dec 14; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonalcoholic-steatohepatitis-compensated-cirrhosis-developing-drugs-treatment-guidance-industry
   Google Scholar
• Anstee QM, Darlay R, Cockell S, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020;73(3):505–515.
   PubMed Web of Science ®Google Scholar
• Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2020;S0168-8278(20):33832.
   Google Scholar
• Francque SM, Bedossa P, Ratziu V, et al. The panPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the NATIVE phase 2b trial [abstract]. Hepatology. 2020;72(S1):9A.
   Google Scholar
• Moroni F, Dwyer BJ, Graham C, et al. Safety profile of autologous macrophage therapy for liver cirrhosis. Nat Med. 2019;25(10):1560–1565.
   PubMed Web of Science ®Google Scholar